WO2023001259A1 - Préparation et utilisation d'un vaccin de protéine trimère du nouveau coronavirus multivalent recombinant capable d'induire une activité à large spectre et de neutralisation - Google Patents
Préparation et utilisation d'un vaccin de protéine trimère du nouveau coronavirus multivalent recombinant capable d'induire une activité à large spectre et de neutralisation Download PDFInfo
- Publication number
- WO2023001259A1 WO2023001259A1 PCT/CN2022/107213 CN2022107213W WO2023001259A1 WO 2023001259 A1 WO2023001259 A1 WO 2023001259A1 CN 2022107213 W CN2022107213 W CN 2022107213W WO 2023001259 A1 WO2023001259 A1 WO 2023001259A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- strain
- immunogenic
- seq
- adjuvant
- protein
- Prior art date
Links
- 239000013638 trimer Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims description 6
- 230000003472 neutralizing effect Effects 0.000 title abstract description 26
- 241000711573 Coronaviridae Species 0.000 title abstract description 10
- 230000001939 inductive effect Effects 0.000 title abstract description 4
- 229940023143 protein vaccine Drugs 0.000 title abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 68
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 62
- 239000002671 adjuvant Substances 0.000 claims abstract description 44
- 229960005486 vaccine Drugs 0.000 claims abstract description 44
- 230000005847 immunogenicity Effects 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 230000002163 immunogen Effects 0.000 claims description 84
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 241001678559 COVID-19 virus Species 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 25
- 108091033319 polynucleotide Proteins 0.000 claims description 18
- 102000040430 polynucleotide Human genes 0.000 claims description 18
- 239000002157 polynucleotide Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 102000002689 Toll-like receptor Human genes 0.000 claims description 6
- 108020000411 Toll-like receptor Proteins 0.000 claims description 6
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims description 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 4
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 4
- 241000241413 Propolis Species 0.000 claims description 4
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 4
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 229960001614 levamisole Drugs 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 229940069949 propolis Drugs 0.000 claims description 4
- 229940031439 squalene Drugs 0.000 claims description 4
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000035772 mutation Effects 0.000 abstract description 14
- 229940031348 multivalent vaccine Drugs 0.000 abstract description 10
- 241000699670 Mus sp. Species 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 230000004727 humoral immunity Effects 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 238000005829 trimerization reaction Methods 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 abstract 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000007969 cellular immunity Effects 0.000 abstract 1
- 235000004252 protein component Nutrition 0.000 abstract 1
- 230000003053 immunization Effects 0.000 description 18
- 238000006386 neutralization reaction Methods 0.000 description 17
- 238000002649 immunization Methods 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 102100024233 High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Human genes 0.000 description 13
- 101001117267 Homo sapiens High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Proteins 0.000 description 13
- 230000028993 immune response Effects 0.000 description 13
- 102100031673 Corneodesmosin Human genes 0.000 description 12
- 101710139375 Corneodesmosin Proteins 0.000 description 12
- 229940031416 bivalent vaccine Drugs 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 8
- 241001112090 Pseudovirus Species 0.000 description 7
- 229940031346 monovalent vaccine Drugs 0.000 description 7
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 229940031418 trivalent vaccine Drugs 0.000 description 7
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 5
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 5
- 229940096437 Protein S Drugs 0.000 description 5
- 101710198474 Spike protein Proteins 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000021633 leukocyte mediated immunity Effects 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 229940031351 tetravalent vaccine Drugs 0.000 description 4
- 229940022962 COVID-19 vaccine Drugs 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 108700021021 mRNA Vaccine Proteins 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229940126583 recombinant protein vaccine Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 229940026232 Novavax COVID-19 vaccine Drugs 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000091 immunopotentiator Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 229940126582 mRNA vaccine Drugs 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000007500 overflow downdraw method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- 108700022172 2019-nCoV Vaccine mRNA-1273 Proteins 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108700022167 ChAdOx1 nCoV-19 Proteins 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 1
- 241001533413 Deltavirus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229940033332 HIV-1 vaccine Drugs 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940026207 Moderna COVID-19 vaccine Drugs 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940025109 Oxford–AstraZeneca COVID-19 vaccine Drugs 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229940026233 Pfizer-BioNTech COVID-19 vaccine Drugs 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 229940124679 RSV vaccine Drugs 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010042365 Virus-Like Particle Vaccines Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne un vaccin de protéine trimère du nouveau coronavirus multivalent recombinant capable d'induire une activité à large spectre et de neutralisation. Le composant de protéine recombinante comprend, mais n'est pas limité à, une protéine homotrimère formée par introduction, dans un domaine extracellulaire (ECD) de protéines de spécule (S) de la souche B.1.617.1 et de la souche B.1.617.2, d'un site de mutation et d'une structure d'aide à la trimérisation. Le vaccin multivalent comprend une protéine trimère ECD d'un seul composant ou toute combinaison de composants des souches de variants ci-dessus, et un adjuvant pharmaceutiquement acceptable. La combinaison de vaccin présente une excellente immunogénicité chez les souris, et peut maintenir une immunité humorale à long terme et une immunité cellulaire. Le vaccin de protéine trimère du nouveau coronavirus multivalent peut être utilisé pour prévenir des maladies liées à une infection provoquées par une infection par le nouveau coronavirus et des souches de variants de celui-ci.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202280035290.6A CN117295756A (zh) | 2021-07-23 | 2022-07-22 | 一种可诱导广谱中和活性重组多价新冠病毒三聚体蛋白疫苗的制备及应用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110838359 | 2021-07-23 | ||
| CN202110838359.6 | 2021-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023001259A1 true WO2023001259A1 (fr) | 2023-01-26 |
Family
ID=84979749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2022/107213 WO2023001259A1 (fr) | 2021-07-23 | 2022-07-22 | Préparation et utilisation d'un vaccin de protéine trimère du nouveau coronavirus multivalent recombinant capable d'induire une activité à large spectre et de neutralisation |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN117295756A (fr) |
| WO (1) | WO2023001259A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024086575A1 (fr) | 2022-10-17 | 2024-04-25 | BioNTech SE | Combinaison de vaccins contre une infection au coronavirus, une infection grippale et/ou une infection à vrs |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050053622A1 (en) * | 2001-08-09 | 2005-03-10 | Andre Aubert | Anti-coronavirus vaccine |
| WO2018115527A2 (fr) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Vaccin contre le coronavirus du syndrome respiratoire du moyen-orient |
| CN112300253A (zh) * | 2020-06-29 | 2021-02-02 | 斯克里普斯研究院 | 稳定的冠状病毒刺突(s)蛋白抗原和相关疫苗 |
| CN112358533A (zh) * | 2020-10-30 | 2021-02-12 | 上海泽润生物科技有限公司 | 重组刺突蛋白及其制备方法和用途 |
| CN112552380A (zh) * | 2020-12-10 | 2021-03-26 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原及其应用 |
-
2022
- 2022-07-22 WO PCT/CN2022/107213 patent/WO2023001259A1/fr unknown
- 2022-07-22 CN CN202280035290.6A patent/CN117295756A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050053622A1 (en) * | 2001-08-09 | 2005-03-10 | Andre Aubert | Anti-coronavirus vaccine |
| WO2018115527A2 (fr) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Vaccin contre le coronavirus du syndrome respiratoire du moyen-orient |
| CN112300253A (zh) * | 2020-06-29 | 2021-02-02 | 斯克里普斯研究院 | 稳定的冠状病毒刺突(s)蛋白抗原和相关疫苗 |
| US20210139543A1 (en) * | 2020-06-29 | 2021-05-13 | The Scripps Research Institute | Stabilized Coronavirus Spike (S) Protein Immunogens and Related Vaccines |
| CN112358533A (zh) * | 2020-10-30 | 2021-02-12 | 上海泽润生物科技有限公司 | 重组刺突蛋白及其制备方法和用途 |
| CN112552380A (zh) * | 2020-12-10 | 2021-03-26 | 武汉博沃生物科技有限公司 | 一种SARS-CoV-2病毒的免疫原及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| LI PEILIN, LIU HAI-YING: "Advances in molecular structure and mechanism of SARS-CoV-2 invading cells", CHINESE BULLETIN OF LIFE SCIENCES, vol. 33, no. 3, 31 March 2021 (2021-03-31), pages 337 - 345, XP093026431, ISSN: 1004-0374, DOI: 10.13376/j.cbls/2021037 * |
| OLMEDILLAS EDUARDO, MANN COLIN J., PENG WEIWEI, WANG YING-TING, AVALOS RUBEN DIAZ, BEDINGER DAN, VALENTINE KRISTEN, SHAFEE NORAZIZ: "Structure-based design of a highly stable, covalently-linked SARS-CoV-2 spike trimer with improved structural properties and immunogenicity", BIORXIV, 6 May 2021 (2021-05-06), XP093026385, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.05.06.441046v1.full.pdf> [retrieved on 20230223], DOI: 10.1101/2021.05.06.441046 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024086575A1 (fr) | 2022-10-17 | 2024-04-25 | BioNTech SE | Combinaison de vaccins contre une infection au coronavirus, une infection grippale et/ou une infection à vrs |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117295756A (zh) | 2023-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saunders et al. | Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses | |
| US11382968B2 (en) | Coronavirus immunogenic compositions and uses thereof | |
| Joyce et al. | SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity | |
| Sternberg et al. | Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination | |
| Vasireddy et al. | Review of COVID-19 vaccines approved in the United States of America for emergency use | |
| Denis et al. | Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization | |
| Li et al. | SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates | |
| Sui et al. | Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant | |
| Begum et al. | Challenges and prospects of COVID‐19 vaccine development based on the progress made in SARS and MERS vaccine development | |
| US9731006B2 (en) | Attenuated recombinant vesicular stomatitis virus vaccine vectors comprising modified matrix proteins | |
| JP2023524054A (ja) | ベータコロナウイルスの予防と治療 | |
| Li et al. | Self-assembling nanoparticle vaccines displaying the receptor binding domain of SARS-CoV-2 elicit robust protective immune responses in rhesus monkeys | |
| US20210260181A1 (en) | Coronavirus immunogenic compositions and uses thereof | |
| Guirakhoo et al. | A Novel SARS-CoV-2 multitope protein/peptide vaccine candidate is highly immunogenic and prevents lung infection in an AAV hACE2 mouse model and non-human primates | |
| WO2023001259A1 (fr) | Préparation et utilisation d'un vaccin de protéine trimère du nouveau coronavirus multivalent recombinant capable d'induire une activité à large spectre et de neutralisation | |
| WO2014205579A1 (fr) | Protéines de matrice modifiées du virus de la stomatite vésiculaire | |
| WO2023160654A1 (fr) | Préparation et utilisation d'un vaccin à composants multiples à base de protéine trimérique de sars-cov-2 recombinante capable d'induire une activité de neutralisation à large spectre | |
| Pecetta et al. | Immunology and technology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines | |
| Schulze et al. | A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus | |
| RU2751485C1 (ru) | Вакцина против гриппа типа А, гриппа типа B и COVID-19 | |
| WO2022253134A1 (fr) | Procédé pour améliorer l'immunogénicité/la stabilité de trimère antigénique d'un antigène ecd de souche mutante de sars-cov-2 | |
| WO2024032468A1 (fr) | Préparation et utilisation d'un vaccin à protéine trimère du sars-cov-2 à cinq composants recombinant pouvant induire une activité de neutralisation à large spectre | |
| WO2023023940A1 (fr) | Immunogène destiné à induire un vaccin à lymphocytes t anti-coronavirus à large spectre et son utilisation | |
| CN115477703A (zh) | 一种提高SARS-CoV-2突变毒株ECD抗原免疫原性/抗原三聚体稳定性的方法 | |
| US20210340188A1 (en) | Recombinant gp120 protein with v1-loop deletion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22845422 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |